Matt Zuga - 17 Jan 2023 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role: CFO and Chief Business Officer
Signature: /s/ Katherine Denby, Attorney-in-Fact
Issuer symbol: ABOS
Transactions as of: 17 Jan 2023
Transactions value $: $0
Form type: 4
Filing time: 18 Jan 2023, 15:27:06 UTC
Previous filing: 03 Jan 2023
Next filing: 04 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABOS	Common Stock	Award	$0	+33.5K	+43.97%	$0.00	110K	17 Jan 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABOS	Employee Stock Option (right to buy)	Award	$0	+151K		$0.00	151K	17 Jan 2023	Common Stock	151K	$6.11	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date.
F2	The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.